Associated Papers
Novel molecular mechanisms of FLT3 deregulation: from the acute myeloid leukemia experience to therapeutic insights in acute lymphoblastic leukemia.
Lo Schiavo F et al.
Molecular Cancer, 2025
41126239 (PubMed )
Supplement: 12943_2025_2455_MOESM2_ESM.xlsx › Table_S1
Landscape of FLT3 Variations Associated with Structural and Functional Impact on Acute Myeloid Leukemia: A Computational Study.
Mirza Z et al.
International Journal of Molecular Sciences, 2024
RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia.
Kubota H et al.
Blood Advances, 2024
38127276 (PubMed )
Supplement: BLOODA_ADV-2023-011583-mmc1.xlsx › Sup.9
Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia.
Gutierrez-Camino A et al.
British Journal of Cancer, 2024
38049555 (PubMed )
Supplement: 41416_2023_2511_MOESM1_ESM.pdf
A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.
Yamaura T et al.
Blood, 2018
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
Nguyen B et al.
Oncotarget, 2017
FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.
Ma HS et al.
Cancer Research, 2014
Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia.
Kang HJ et al.
Leukemia Research, 2005
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
Yamamoto Y et al.
Blood, 2001
Select a paper to view details